InvestorsHub Logo
icon url

cjgaddy

06/11/15 9:01 AM

#223170 RE: cjgaddy #221526

Follow-up on BMY’s Ph3 Opdivo NSCLC trial – look at the KM-Curve and OS #’s for those pts that express < 10% PD-L1. Tthe OS separation in the tail just collapses and Opdivo (nivolumab) dead standstill with Doce in MOS => That’s ~64% of ALL the pts in the n=582 trial! …Thus the window of opportunity for Bavi is essentially 2/3 of the NSCLC market. Of course, the other 1/3 of the patients where Opdivo works well might live even longer if Bavi were added to the mix….

http://investor.bms.com/files/doc_presentations/2015/ASCO-Investor-Presentation-June-1-FINAL_v001_p9iq7v.pdf (pg.25)




= = = = = = = = = = = = = = = = = = = =
5-30-15: PD-1/PD-L1 blockade therapies like Opdivo+Keytruda benefit 20-25% of patients. Peregrine’s objective with Bavi is to “increase the extent & amplitude” of such therapies…
“Although PD-1/PD-L1 blockade therapy [ex: Opdivo, Keytruda ] provides clinical benefits to approx. 20% of patients with advanced NSCLC, about 80% of patients still remain refractory to this treatment. Therefore, new molecules & combinations are urgently needed to address primary & secondary resistance to these new agents.
From 3-2015 ClinCancerRes. article, “Immune Checkpoint Modulation for Non–Small Cell Lung Cancer”:
http://clincancerres.aacrjournals.org/content/21/10/2256.abstract
http://www.ncbi.nlm.nih.gov/pubmed/25979932
=> Enter BAVI, stage left, whose objective is to Extend The Range of patients that would benefit from the anti-PD1 mabs, in addition to helping the 20% that do benefit get Better Results.

= = = = = = = = = = = = = = = = = = = =
5-29-15: Peregrine Pharmaceuticals Enters Into Research Collaboration [with Mem. Sloan Kettering] to Investigate Novel PS-Targeting Immunotherapy Combinations
• Research Collaboration to Focus on Exploring Potential Combinations of PS-Targeting Agents Including Bavituximab With Other Immune Modulators
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114118480
"The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said (Sloan’s) Dr. Jedd D. Wolchok.
. . .
As part of the collaboration, researchers at MSK will conduct research to further explore the combination of PS-targeting agents, including bavituximab, that block a primary immunosuppressive pathway thereby allowing anti-tumor immune responses with other immuno-stimulatory agents that enhance immune responses. Specifically, MSK researchers will examine the combination of bavituximab alongside models of checkpoint blockade that are unresponsive to inhibition or co-stimulation given the ability of bavituximab to reprogram myeloid derived suppressor cells (MDSC) and increase tumoricidal T-cells in tumors, a mechanism of action that is complementary to checkpoint blockade and T-cell activation.
. . .
"A key focus of the Wolchok Lab's research is studying novel immunotherapy combinations that work together to enable the immune system to recognize and destroy cancer. This collaboration will allow us to focus on the role and contribution of PS blockade therapy in determining which combination of the current and next generation of immune modulators is likely to increase the extent and amplitude of anti-tumor response. This important pre-clinical and translational work will potentially guide the design of the next generation of clinical studies with bavituximab," said (Sloan’s) Dr. Taha Merghoub.
. . .
"We are delighted to be working with a world-renowned pioneer and leader in the immuno-oncology space, recognizing that there remains significant research in order for more cancer patients to realize the benefits of combination immune therapy," said Jeff T. Hutchins, PhD, VP of Preclin. Research at Peregrine. "Our internal & collaborative research presented over the last year has established a robust foundation of PS-targeting activity on which to initiate this next chapter in PS research and development."
icon url

cjgaddy

06/15/15 12:12 PM

#223635 RE: cjgaddy #221526

PPHM SAB’r Dr.Xianming.Huang(Brekken Lab) speaks tonight at Gordon-Research-Conf., Biddeford ME

Jun14–19 2015: “GRC: Apoptotic Cell Recognition & Clearance: Physiological Significance & Pathological Consequences”, Biddeford ME
GRC = Gordon Research Conferences (Univ. of New England) http://www.grc.org
”This 7th meeting of the Apoptotic Cell Recognition & Clearance Gordon Research Conf. will explore molecular details of apoptotic cell recognition and clearance mechanisms throughout evolution, including apoptotic immune regulation. We also will focus on the pathogenic subversion of mechanisms of apoptotic cell clearance. This meeting will bring together investigators who are at the forefront of these fields to present and discuss new findings & important issues…”
• Peregrine is the only corporate contributor to this conference: ”Generous financial support from Peregrine Pharmaceuticals is in memory of Dr. Philip E. Thorpe.” [Dr. Thorpe spoke & chaired at prior GRC’s many times before his passing on 3-30-13.]
Conf: http://www.grc.org/programs.aspx?id=13127
JUNE15 SESSION 7:30-9:30pm “Consequences of Lipid Alterations for Apoptotic Cell Clearance”
…Discussion Leader: Christopher Gregory (Univ. of Edinburgh, UK)
• 7:30-7:55pm Ian Dransfield (Univ/Edinburgh UK), "Protein S Binding to Apoptotic Cells & Subsequent Phagocytosis by Macrophages"
• 8:10-8:35pm Raymond Birge (Rutgers NJ Med-School), "Apoptotic Cell Recognition Receptors, Tyro3/Axl/Mer, Demonstrate Distinct Patterns of Ligand Recognition & Biological Function"
• June15 8:50-9:15pm Xianming Huang (UTSW-MC/Dallas – PPHM SAB/Brekken-Lab), "Phosphatidylserine-Targeting Antibodies Overcome Tumor Immunosuppression & Synergize with Immune Checkpoint Blockade"

= = = = = = = = = = = =KNOWN UPCOMING:
Jun15: GRC’s “7th Apoptotic Cell Recognition & Clearance Conf.”, Biddeford ME http://www.grc.org/programs.aspx?id=13127
…8:50-9:15pm: Xianming Huang (UTSW), “PS-Targeting Antibodies Overcome Tumor Immunosuppression & Synergize with Immune Checkpoint Blockade"

~Jul13: FY'15/Q4 (fye 4-30-15) Financials & Conf. Call http://ir.peregrineinc.com/events.cfm

Jun15-18/Avid/Booth533: BIO Intl. Convention, Philadelphia http://convention.bio.org/2015

Aug26: CHI’s 10th Annual Immunotherapy & Vaccine Summit (IMVACS), Boston http://tinyurl.com/lfdoksl
… 9-9:30 Jeff T. Hutchins (VP/Preclin-Res.): “Expansion and Activation of T Cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”

Sep6-9: IASLC’s 16th World Conf. on Lung Cancer”, Denver http://tinyurl.com/qdteoc8
…Peregrine Exhibiting, Booth #1724 (KOL/SAB Dr. David Carbone will be President of IASLC eff. 9-2015)

Oct26-29/Avid/Booth909: IBC's BioProcess Intl. Conf. & Exhib, Boston http://www.ibclifesciences.com/BPI

Dec7-10/Avid/Booth307: IBC's Antibody Eng. & Therapeutics, SanDiego http://www.ibclifesciences.com/AntibodyEng

Mar15-17 2016: “Immune Checkpoint Inhibitors Conf.”, Boston http://immune-checkpoint.com (Peregrine is 1 of 4 Corp. Sponsors)
icon url

cjgaddy

07/10/15 1:33 PM

#225761 RE: cjgaddy #221526

Ph.3/NSCLC SUNRISE #Sites=161 a/o 7-9-15 (39US+122Intl)

• 5-2-14: 25 (All USA)
• 5-29-14: 62 (USA/29 Aus/3 Fr/1 Ger/6 Hungary/4 Korea/4 Spain/13 Taiwan/2)
• 6-9-14: 73 (USA/31 Aus/5 Fr/1 Ger/6 Hungary/4 Korea/4 Rus/7 Spain/13 Taiwan/2)
• 6-19-14: 88 (USA/34 Aus/5 Bel/6 Fr/1 Ger/6 Hungary/6 Italy/1 Korea/5 Rom/1 Rus/6 Spain/14 Taiwan/3)
• 6-25-14: 91 (USA/34 Aus/5 Bel/7 Fr/1 Ger/6 Hungary/6 Italy/0 Korea/7 Rom/1 Rus/6 Spain/14 Taiwan/4)
• 7-2-14: 100 (USA/32 Aus/6 Bel/7 Fr/4 Ger/8 Hungary/6 Korea/7 Rom/4 Rus/6 Spain/15 Taiwan/5)
• 7-9-14: 108 (USA/33 Aus/6 Bel/7 Fr/7 Ger/9 Hungary/7 Korea/7 Rom/6 Rus/6 Spain/15 Taiwan/5)
• 7-23-14: 115 (USA/32 Aus/6 Bel/7 Fr/9 Ger/9 Greece/5 Hungary/7 Korea/7 Rom/6 Rus/6 Spain/15 Taiwan/6)
• 7-28-14: 118 (USA/34 Aus/6 Bel/7 Fr/9 Ger/9 Greece/5 Hungary/7 Korea/7 Rom/6 Rus/6 Spain/15 Taiwan/7)
• 7-31-14: 121 (USA/34 Aus/6 Bel/7 Fr/9 Ger/10 Greece/6 Hungary/7 Korea/7 Rom/6 Rus/6 Spain/15 Taiwan/8)
• 8-7-14: 124 (USA/34 Aus/7 Bel/7 Fr/9 Ger/11 Greece/6 Hungary/7 Korea/7 Rom/6 Rus/6 Spain/16 Taiwan/8)
• 8-13-14: 128 (USA/34 Aus/7 Bel/7 Fr/10 Ger/12 Greece/6 Hungary/7 Italy/2 Korea/7 Rom/6 Rus/6 Spain/16 Taiwan/8)
• 8-20-14: 131 (USA/35 Aus/7 Bel/7 Fr/9 Ger/12 Greece/7 Hungary/7 Italy/2 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/9)
• 8-26-14: 133 (USA/36 Aus/7 Bel/7 Fr/9 Ger/12 Greece/7 Hungary/7 Italy/2 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/10)
• 9-4-14: 135 (USA/37 Aus/7 Bel/7 Fr/9 Ger/12 Greece/7 Hungary/7 Italy/3 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/10)
• 9-17-14: 138 (USA/37 Aus/8 Bel/7 Fr/9 Ger/12 Greece/7 Hungary/7 Italy/3 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/10 Ukraine/2)
• 9-23-14: 141 (USA/37 Aus/8 Bel/7 Fr/9 Ger/12 Greece/8 Hungary/7 Italy/3 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/10 Ukraine/4)
• 10-1-14: 143 (USA/37 Aus/8 Bel/7 Fr/9 Ger/12 Greece/8 Hungary/7 Italy/4 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/10 Ukraine/5)
• 10-17-14: 145 (USA/37 Aus/8 Bel/7 Fr/9 Ger/12 Greece/8 Hungary/7 Italy/5 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/10 Ukraine/6)
• 11-7-14: 148 (USA/37 Aus/8 Bel/7 Fr/9 Ger/13 Greece/8 Hungary/7 Italy/7 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/10 Ukraine/6)
• 12-1-14: 150 (USA/37 Aus/8 Bel/7 Fr/9 Ger/14 Greece/8 Hungary/7 Italy/8 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/10 Ukraine/6)
• 12-19-14: 152 (USA/38 Aus/8 Bel/7 Fr/9 Ger/14 Greece/9 Hungary/7 Italy/8 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/10 Ukraine/6)
• 2-17-15: 154 (USA/38 Aus/8 Bel/7 Fr/9 Ger/14 Greece/9 Hungary/7 Italy/10 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/10 Ukraine/6)
• 3-23-15: 156 (USA/38 Aus/8 Bel/7 Fr/9 Ger/15 Greece/10 Hungary/7 Italy/10 Korea/7 Rom/6 Rus/7 Spain/16 Taiwan/10 Ukraine/6)
• 3-31-15: 158 (USA/38 Aus/8 Bel/7 Fr/9 Ger/15 Greece/10 Hungary/7 Italy/10 Korea/9 Rom/6 Rus/7 Spain/16 Taiwan/10 Ukraine/6)
7-9-15: 161 (USA/39* Aus/9 Bel/7 Fr/9 Ger/15 Greece/10 Hungary/7 Italy/10 Korea/9 Rom/6 Rus/8 Spain/16 Taiwan/10 Ukraine/6) – *NOTE: BaltMD was added 5-6-15.

BAVITUXIMAB PHASE III TRIAL: (see http://PeregrineTrials.com => http://www.SunriseTrial.com )
A. Phase III Bavi+Doce vs. 2nd-Line NSCLC "SUNRISE" (randomized, double-blind, placebo-ctl'd, n=582) (Start=Dec’13 Est PrimaryComp=Dec’16)
USA Protocol: http://www.clinicaltrials.gov/ct2/show/NCT01999673 - 161 sites a/o 7-9-15 (USA/39 Aus/9 Bel/7 Fr/9 Ger/15 Greece/10 Hungary/7 Italy/10 Korea/9 Rom/6 Rus/8 Spain/16 Taiwan/10 Ukraine/6) - Growth: http://tinyurl.com/qbemrr2
…EU/EEA Registries: (pts world=582, pts/EU=345, planned EU sites=100) http://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003953-13
• GER: http://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003953-13/DE (planned sites=14, pts=43)
• SPAIN: http://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003953-13/ES (planned sites=16, pts=100)
• HUNGARY: http://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003953-13/HU (planned sites=9, pts=28)
• GREECE: http://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003953-13/GR (planned sites=9, pts=120)
• ITALY: http://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003953-13/IT (planned pts=55)
• BELGIUM: http://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003953-13/BE (planned sites=7 pts=31)
...EU= European Union (29 countries – see http://www.gov.uk/eu-eea ), EEA=European Economic Area (all the EU, plus Iceland, Liechtenstein, Norway)
…Regions where sites are planned: Australia, Belgium, France, Germany, Greece, Hungary, Italy, Korea, Romania, Russia., Spain, Taiwan, Ukraine, USA
- - - - - -
6-1-15: “Completion of enrollment is anticipated by calendar yr-end.” http://tinyurl.com/qxu4w2x
5-31-14 ASCO’14: David Gerber/Joe Shan Poster on Ph3/SUNRISE Trial (#TPS8129) http://tinyurl.com/nv4jloo
3-7-14: PR & Conf-Call: "first patients enrolled and dosed." http://tinyurl.com/kh9cnrg
1-6-14: FDA grants FAST TRACK status to Bavi in 2ndLine NSCLC http://tinyurl.com/l799ukk
12-30-13: Pivotal Ph.3 ‘SUNRISE’ NSCLC Trial Initiated (n=~600, sites>100) http://tinyurl.com/kdjb9qz
5-20-13: FDA Approves Bavituximab Ph.III Design for 2L/NSCLC; 600-pt trial to begin by y/e’13 http://tinyurl.com/n3dxtm6
...S.King: “We will now focus on starting the Ph.III trial while continuing ongoing partnering discussions.”
…R.Garnick: “This was a highly collaborative effort with the FDA; this trial, when combined with Bavi’s supporting data to date, could be sufficient to support a future BLA submission."

Contact: Jennifer Lai, MBA 1-855-291-SUNR (7867) lungcancertrial@peregrineinc.com
Peregrine Pharmaceuticals’ Clinical Development Group
• A.J. Leyco, RN - Associate Director, Clinical Trials
• Jennifer Lai, MBA, CCRA - Manager, Clinical Research
icon url

cjgaddy

08/24/15 8:32 AM

#231727 RE: cjgaddy #221526

Durvalumab (MEDI4736, anti-PD-L1) has a NPV of $6.5B.
AZN’s Head/I-O(Robert Iannone): “…Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers."



8-24-15: AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial
• Collaboration to Focus on Cancer Immunotherapy Combination of Peregrine's PS-Targeting Bavituximab and AstraZeneca's PD-L1 Inhibitor MEDI4736
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=928488
TUSTIN, Aug. 24, 2015: AstraZeneca (NYSE:AZN) and Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM/PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that they have entered into a cancer immunotherapy clinical trial collaboration. The collaboration will evaluate Peregrine's investigational phosphatidylserine (PS)-signaling pathway inhibitor, bavituximab, in combination with AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumors
. . .
Robert Iannone, Head of Immuno-Oncology, Global Medicines Development, at AstraZeneca said, "We believe that combination therapy in immuno-oncology has the potential to be a novel and highly effective approach to treating cancer. Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers."
. . .
"Data generated to date have shown significant potential for combining bavituximab with agents targeting the PD-1/PDL-1 pathway and we're excited to further explore this approach in studies with AstraZeneca's durvalumab," said Steven W. King, President and CEO of Peregrine. "AstraZeneca is a recognized leader in the immuno-oncology field and this collaboration will play a key role as we continue to fully explore the potential of bavituximab in combination immunotherapies for a variety of clinical applications."
icon url

cjgaddy

08/24/15 9:15 AM

#231750 RE: cjgaddy #221526

8-24-15: AstraZeneca & Peregrine Collaborate on Bavi+Durvalumab Ph1/1B Trial for “multiple solid tumors”…
Durvalumab=MEDI4736, an anti-PD-L1 immune checkpoint inhibitor.
AZN’s Head/I-O(Robert Iannone): “…Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers."

= = = = = = = = = = = = = =
8-24-15: AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial
• Collaboration to Focus on Cancer Immunotherapy Combination of Peregrine's PS-Targeting Bavituximab and AstraZeneca's PD-L1 Inhibitor MEDI4736
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=928488
TUSTIN, Aug. 24, 2015: AstraZeneca (NYSE:AZN) and Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM/PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that they have entered into a cancer immunotherapy clinical trial collaboration. The collaboration will evaluate Peregrine's investigational phosphatidylserine (PS)-signaling pathway inhibitor, bavituximab, in combination with AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumors.

Peregrine and AstraZeneca will collaborate on a non-exclusive basis, to evaluate the combination of bavituximab and durvalumab with chemotherapy as a potential treatment in various solid tumors. The Phase I part of the trial is expected to establish a recommended dose regimen for the combination and the Phase Ib part of the trial will assess the safety and efficacy of the investigational combination. Under the terms of the agreement, the initial trial will be conducted by Peregrine.

Robert Iannone, Head of Immuno-Oncology, Global Medicines Development, at AstraZeneca said, "We believe that combination therapy in immuno-oncology has the potential to be a novel and highly effective approach to treating cancer. Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers."

Bavituximab and durvalumab are investigational immunotherapies with different mechanisms that assist the body's immune system in fighting cancer. Bavituximab targets and modulates the activity of phosphatidylserine, a highly immune-suppressive molecule expressed broadly on the surface of cells in the tumor microenvironment. The treatment increases activated T-cells in tumors and fights cancer by reversing the immunosuppressive environment that many tumors establish in order to proliferate. MEDI4736 is a monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. Preclinical data have demonstrated that combining the enhanced T-cell mediated anti-tumor activity of bavituximab with checkpoint inhibitors, like PD-L1 antibodies, prolong the ability of tumor-specific T-cells to continue attacking the tumor.

"Data generated to date have shown significant potential for combining bavituximab with agents targeting the PD-1/PDL-1 pathway and we're excited to further explore this approach in studies with AstraZeneca's durvalumab," said Steven W. King, President and CEO of Peregrine. "AstraZeneca is a recognized leader in the immuno-oncology field and this collaboration will play a key role as we continue to fully explore the potential of bavituximab in combination immunotherapies for a variety of clinical applications."

ABOUT BAVITUXIMAB: A Targeted Investigational Immunotherapy
Bavituximab is an investigational chimeric monoclonal antibody that targets phosphatidylserine (PS). Signals from PS inhibit the ability of immune cells to recognize and fight tumors. Bavituximab, the lead compound in Peregrine's immuno-oncology development program, blocks PS to remove this immunosuppressive signal and sends an alternate immune activating signal. Targeting PS with bavituximab has been shown to shift the functions of immune cells in tumors, resulting in robust anti-tumor immune responses.

ABOUT DURVALUMAB (MEDI4736)
MEDI4736 is an investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. MEDI4736 blocks these signals, countering the tumor's immune-evading tactics. MEDI4736 is being developed, alongside other immunotherapies, to empower the patient's immune system and attack the cancer.

ABOUT PEREGRINE PHARMACEUTICALS, INC.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials focused on the treatment of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( http://www.avidbio.com ), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit http://www.peregrineinc.com .

ABOUT ASTRAZENECA IN ONCOLOGY?
Oncology is a therapeutic area in which AstraZeneca has a deep-rooted heritage. It will be potentially transformational for the company's future, becoming the sixth growth platform. Our vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as a cause of death. By 2020, we are aiming to bring six new cancer medicines to patients.
Our broad pipeline of next-generation medicines is focused on four main disease areas - ovarian, lung, breast and haematological cancers. These are being targeted through four key platforms - immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates.

ABOUT ASTRAZENECA
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: http://www.astrazeneca.com
Safe Harbor *snip*

Contacts:
• Jay Carlson, Peregrine Pharmaceuticals, Inc., (800) 987-8256, info@peregrineinc.com
• Stephanie Diaz (Investors), Vida Strategic Partners, 415-675-7401, sdiaz@vidasp.com
• Tim Brons (Media), Vida Strategic Partners, 415-675-7402, tbrons@vidasp.com

= = = = = = = = = = = = = = = = = = =
Durvalumab (MEDI4736, anti-PD-L1) has a Net Present Value of $6.5B.

AZN’s Head/I-O(Robert Iannone): “…Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers."


= = = = = = = = = = = = = = =
SCIENCE: "Evolution has favored pathogenesis that resembles apoptosis."
Dr. Judah Folkman: ”This [Thorpe’s VTA research] is very promising and very elegant work... The whole goal is really 2-part, reducing the harsh side effects of cancer treatment, and reducing the chance that some cancer cells will evade treatment. That would be a big step in the next decade, and anti-vascular therapy will play a major role." (’97 & ’02 http://tinyurl.com/k5qe96g & http://tinyurl.com/n6vh9hp )
Peregrine's Bavituximab Clinical Trials website: http://PeregrineTrials.com
BAVITUXIMAB MOA & CLINICAL DATA: http://www.peregrineinc.com/pipeline/bavituximab-oncology.html
...Bavi Publications: http://www.peregrineinc.com/publications/publications.html
...Bavi Posters & Presentations: http://www.peregrineinc.com/publications/posters-and-presentations.html
Bavi MOA: Video (3:34) added ~3-2014 http://vimeo.com/87116642 "Bavituximab: A Novel Immunotherapy Candidate Targeting an Upstream Immune Checkpoint to Fight Cancer"
Bavi MOA: Video (1:33) on Bavi’s Immunotherapeutic MOA added to Youtube on 3-27-14 https://www.youtube.com/watch?v=Esewl35JD8s

5-31-15: ASCO’15 Roundtable (webcast), “Raising the Immuno-Oncology Bar” - 7 panel members, incl. 3 Sloan Kettering researchers http://tinyurl.com/qxu4w2x
BAVI MOA 3-25-15: PPHM/VP Dr. Jeff Hutchins’ presentation at "Immune Checkpoint Inhibitors Conf.", Boston - PDF(34 Slides): http://tinyurl.com/ooxkhq7
BAVI MOA 2-9-15: PPHM/VP Dr. Bruce Freimark’s presentation at KEYSTONE "Tumor Immunology Meeting", Banff/CN – PR & Slides: http://tinyurl.com/q6cx4w6
BAVI MOA 12-12-14 San Antomio Breast Cancer Symposium, Dr. Bruce Freimark, Bavi+anti-PD-1 vs. Breast Cancer http://tinyurl.com/p5ng6vs
BAVI MOA 11-2014 SITC’14: 3 posters on preclin. Bavi+aCTLA4/aPD1 combo data (Hutchins Freimark Brekken Huang etal) http://tinyurl.com/pchzr6h
BAVI MOA 8-28-14: Italy’s Dr. Federico Cappuzzo, Bavi/NSCLC profile article (DovePress OpenAccess, 7pgs) - http://tinyurl.com/n3oa7bc
BAVI MOA 8-11-14: PPHM/VP Dr. Jeff Hutchins’ presentation at ImVacS "Immunotherapies & Vaccine Summit", Boston - PR: http://tinyurl.com/lpjy3u7 ; PDF(31 Slides): http://tinyurl.com/oueldme
...MLV’s Dr. George Zavoico’s 8-27-14 report on Dr. Jeff Hutchins’ 8-11-14 ImVacS/Boston Bavi MOA presentation: http://tinyurl.com/l3tw63c
BAVI MOA 5-28-14: Dr. Rolf Brekken’s 47min CRI “Cancer Immunotherapy” webinar about Bavituximab as an Upstream/Global Immune Checkpoint Inhibitor – REPLAY: http://tinyurl.com/lxgftyx
. . .CRI=Cancer Research Institute (NYC – Supported by BMS): http://www.cancerresearch.org - Facebook: http://tinyurl.com/pbmhb2z , https://twitter.com/CancerResearch
. . .CRI launches “Answer to Cancer” (cancer immunotherapy) website http://www.theanswertocancer.org
. . .8-12-14: CRI adds Youtube links to the 5-28-14 CRI Immunotherapy webinar, incl. Dr. Brekken's talk "about Bavi and how it works against lung, liver, and other kinds of cancers" http://tinyurl.com/ps5h6h8
BAVI MOA 3-25-14: Dr. Rolf Brekken’s 40min talk at NYAS Lung Cancer Symposium http://tinyurl.com/lq9stnk (45 Slides)
. . .Dr.Brekken’s talk: “Antibody-mediated Inhibition of PS - A Novel Strategy for Immune Checkpoint Blockade” (the 5 speakers: Jessica Donington, Roy Herbst, Balazs Halmos, Suresh Ramalingam, Rolf Brekken)
12-10-13: With recent scientific insights highlighting bavi’s immunostimulatory moa, these additions to PPHM’s SAB: Dimitry Gabrilovich, Scott Antonia, David Carbone**, Hakan Mellstedt http://tinyurl.com/mw776mk
......**A/o 9-2014, Dr. David Carbone (PPHM SAB/KOL) is President-Elect of IASLC https://www.iaslc.org/about-us/board
BAVI MOA: 12-2013 Bavi’s Immunotherapeutic MOA overviewed by UTSW’s Brekken/Huang in Pan European Networks Jrnl. http://tinyurl.com/lnb46pq
BAVI MOA 11-9-13: Annual SITC (WashDC) – 2 posters about Bavi’s Immunostimulatory MOA http://tinyurl.com/mjaweu5
...“We are actively working towards initiating a clinical trial in the coming months to further investigate the potential synergistic effects of bavituximab and an approved [anti-CTLA-4] immunotherapy in patients with Melanoma."
10-28-13 IASLC/Sydney: “Immune Checkpoints in the Tumor Environment: Novel Targets & the Clinical Promise of Combined Immunotherapies” http://tinyurl.com/mjaweu5
…Symposium speakers: Scott J. Antonia/MD-PhD(H.Lee Moffitt CC), Dmitry I. Gabrilovich/MD-PhD(Wistar Inst), Rolf A. Brekken/PhD(UTSW), David E. Gerber/MD(UTSW)
BAVI MOA: 8-19-13 Data Supporting Bavituximab’s Immunotherapy MOA Published in “Cancer Immunology Research” (AACR) - http://tinyurl.com/mhjftka (PDF)
…“PS-Targeting Antibody Induces M1 Macrophage Polarization & Promotes Myeloid-Derived Suppressor Cell Differentiation” (Thorpe etal)
BAVI MOA: 8-13-13 PPHM/VP Dr. Jeff Hutchins’ Presentation on the Downstream Immunostimulatory Effects/Moa of PS-targeting antibodies (like Bavi) at CHI’s “Immunotherapies Congress”/Boston http://tinyurl.com/m6h2tvt
BAVI MOA: 10-12-12 NMB article on how Bavi "Induces Innate & Specific Anti-tumor Responses" http://tinyurl.com/cw9odb8
BAVI MOA: 5-1-12 Dr. Phil Thorpe's 46min talk at NYAS PS-Targeting Symposium http://tinyurl.com/9792gl5
. . .Symposium title: "Phosphatidylserine (PS) Asymmetry - Therapeutic Apps. in Cancer & Infectious Disease Symposium"
. . .Replays of 5 speakers: Alan Schroit, Chris Reutlingsperger, David Ucker, Ari Helenius, Philip Thorpe
icon url

cjgaddy

09/11/15 8:10 AM

#234584 RE: cjgaddy #221526

9-10-15/OutsourcingPharma: “Avid Revs Likely to Grow Substantially”

9-10-15: “Peregrine Up on CMO Q1 Sales & Backlog, as New Plant Set to go Online”
By Dan Stanton, Outsourcing-Pharma
http://www.outsourcing-pharma.com/Contract-Manufacturing/Peregrine-up-on-CMO-sales-and-backlog-as-new-plant-set-to-go-online
Manufacturing backlog at Avid Bioservices has reached $42mm as the firm books up space at a new facility currently undergoing its first internal pilot run. For Q1/FY2016, Peregrine Pharmaceuticals reported record revenue from its contact manufacturing business Avid Bioservices of $9.4mm, up 71% year-on-year. But revenues are likely to grow substantially, the firm said, as there is a $42mm committed backlog from existing customers which will be carried-out in part once a new mammalian cell culture manufacturing facility in Tustin, California comes online.

“The new manufacturing suite is fully built and the first internal pilot run is currently underway to verify all systems and equipment are properly functioning,” Peregrine CFO Paul Lytle said during an investor call yesterday. ”Our strategic investment in the Avid Bioservices business is already starting to pay dividends. Our clients are reserving manufacturing slots in the new facility which has increased our revenue backlog to approximately $42mm.”

A large proportion of the firm’s revenues come from its major client, Halozyme Therapeutics, servicing monoclonal antibody development projects with Roche and Baxter. While the company hopes the new facility will attract new customers, it is the current customer base showing the most interest.

“In the new facility, a lot of the interest comes from the existing client base, even as much as we've had new potential customers coming through,” said CEO Steven King. “It's exciting, it's a real nice showpiece and it's really showing in the interest that it's generated from again the existing client base.”

The site, first announced last year, more than doubles Avid’s manufacturing capacity, though some of the space has been reserved to service its parent company’s lead product bavituximab, a chimeric mAb in Phase III trials for non-squamous non-small cell lung cancer. END



• 6-17-15: Avid’s John Haney (ex-Genentech/Pfizer) speaking at BIO-INTL’5/Philly http://tinyurl.com/pnlquu3 & http://tinyurl.com/nl4vbgk
...”Designing & Implementing Avid’s New State-of-the-Art Single-Use Facility for Late Ph.3 & Commercial Prod.” - SK: "We've seen tremendous interest for production in the new facility, both from new & existing clients"
• 12-10-14: Avid to Double Mfg. Capacity (“expanding client roster; potential commercial launch of bavituximab”) http://tinyurl.com/mmc3qgy & http://tinyurl.com/kmdgq8t
• 3-24-15: Avid Receives CMO Leadership Awards for Its Commitment to Innovation & Reliability http://tinyurl.com/psep47f
• 3-12-13: Avid Q3'FY13 GP=$3.3mm; S.King 3-2012, "We have a profitable CMO, Avid Bioservices" http://tinyurl.com/l97rzm8

= = = = = = = = = = = = = = = = = = = = = = = = = = = =
Updated PPHM REVS-BY-QTR TABLE, now thru FY16/Q1 (q/e 7-31-15), per the 7-31-15 10-Q ( http://tinyurl.com/pemub47 ) issued 9-9-15.
• Total Revs since May’06: ($138.6mm/Avid + $24.1mm/Govt + $2.4mm/Lic.) = $165.2mm
Deferred-Revs at 7-31-15, going fwd into FY’16/Q2 (q/e 10-31-15), total $8.3mm, UP from the $6.6mm of Deferred-Revs at 4-30-15 that drove into FY’16/Q1.
• Avid’s Gross-Profit over last 3 qtrs: $12.5mm on revs of $24.4mm (GP% = 49%)
• Recall, Avid Rev$ from Gov’t DTRA Contract work (6/30/08 – 4/15/11, totaling $24.15mm), went into GOVT-REVS, not AVID-REVS, in the Financials.
Avid’s website: http://www.avidbio.com
 
AVID PROFITABILITY (GROSS*) BY QTR:
QTR Avid-Rev$ CostofMfg$ Gross-Profit$ GP%
FY13Q1 7-31-12 4,135,000 2,024,000 2,111,000 51%
FY13Q2 10-31-12 6,061,000 3,703,000 2,358,000 39%
FY13Q3 1-31-13 6,961,000 3,651,000 3,310,000 47%
FY13Q4 4-30-13 4,176,000 3,217,000 959,000 23%
FY13 TOTAL: 21,333,000 12,595,000 8,738,000 41%*
FY14Q1 7-31-13 4,581,000 2,670,000 1,911,000 42%
FY14Q2 10-31-13 7,354,000 4,195,000 3,159,000 43%
FY14Q3 1-31-14 3,885,000 2,416,000 1,469,000 38%
FY14Q4 4-30-14 6,474,000 3,829,000 2,645,000 41%
FY14 TOTAL: 22,294,000 13,110,000 9,184,000 41%*
FY15Q1 7-31-14 5,496,000 3,583,000 1,913,000 35%
FY15Q2 10-31-14 6,263,000 4,139,000 2,124,000 34%
FY15Q3 1-31-15 5,677,000 3,113,000 2,564,000 45%
FY15Q4 4-30-15 9,308,000 4,758,000 4,550,000 49%
FY15 TOTAL: 26,744,000 15,393,000 11,151,000 42%*
FY16Q1 7-31-15 9,379,000 4,608,000 4,771,000 51%
*Avid Net-Profit (ie, incl. Selling, G&A) not split out from PPHM-Corp. in the financials.
.
PPHM REVENUES (in thousands) DEFERRED
-------REVENUES------- REVENUES INVEN-
Quarter Avid Govt Lic. TOTAL Avid Govt TORIES
FY07Q1 7-31-06 398 0 23 421 317 0 971
FY07Q2 10-31-06 636 0 48 684 1388 0 1899
FY07Q3 1-31-07 347 0 16 363 2202 0 1325
FY07Q4 4-30-07 2111 0 129 2240 1060 0 1916
FY08Q1 7-31-07 1621 0 4 1625 1820 0 2363
FY08Q2 10-31-07 1863 0 29 1892 1338 0 3500
FY08Q3 1-31-08 1662 0 13 1675 1434 0 2394
FY08Q4 4-30-08 751 0 150 901 2196 0 2900
FY09Q1 7-31-08 1193 324 0 1517 4021 980 4628
FY09Q2 10-31-08 983 958 0 1941 6472 1701 6700
FY09Q3 1-31-09 5778 1048 0 6826 4805 3262 5547
FY09Q4 4-30-09 5009 2683 175 7867 3776 3871 4707
FY10Q1 7-31-09 2070 4671 9 6750 5755 2332 6177
FY10Q2 10-31-09 5308 1510 78 6896 4260 3989 5850
FY10Q3 1-31-10 2945 6854 78 9877 3052 76 3861
FY10Q4 4-30-10 2881 1461 78 4420 2406 78 3123
FY11Q1 7-31-10 983 2111 115 3209 3719 47 4692
FY11Q2 10-31-10 3627 966 78 4671 2447 35 3555
FY11Q3 1-31-11 1922 882 79 2883 4300 40 3915
FY11Q4 4-30-11 1970 681 78 2729 5617 0 5284
FY12Q1 7-31-11 5439 0 216 5655 4145 0 4481
FY12Q2 10-31-11 4154 0 78 4232 2012 0 3178
FY12Q3 1-31-12 3203 0 78 3281 2552 0 2722
FY12Q4 4-30-12 1987 0 78 2065 3651 0 3611
FY13Q1 7-31-12 4135 0 116 4251 6056 0 5744
FY13Q2 10-31-12 6061 0 78 6139 6221 0 5426
FY13Q3 1-31-13 6961 0 78 7039 5061 0 4635
FY13Q4 4-30-13 4176 0 78 4254 4171 0 4339
FY14Q1 7-31-13 4581 0 107 4688 4164 0 5679
FY14Q2 10-31-13 7354 0 0 7354 3468 0 4033
FY14Q3 1-31-14 3885 0 0 3885 4329 0 5224
FY14Q4 4-30-14 6474 0 0 6474 5241 0 5530
FY15Q1 7-31-14 5496 0 0 5496 4670 0 5998
FY15Q2 10-31-14 6263 0 37 6300 3612 0 5379
FY15Q3 1-31-15 5677 0 0 5677 5752 0 6148
FY15Q4 4-30-15 9308 0 0 9308 6630 0 6148
FY16Q1 7-31-15 9379 0 292 9671 8291 0 10457
Totals: 129212 24149 2416 165156 <=since5/1/2006
.
TOTAL REV’s BY YEAR (Avid+Gov’t+Lic):
FY04 4-30-04 3,314 …Avid(CMO)= 3,039 (Avid-Revs don’t incl. Govt-SVCS)
FY05 4-30-05 4,959 …Avid(CMO)= 4,684
FY06 4-30-06 3,193 …Avid(CMO)= 3,005
FY07 4-30-07 3,708 …Avid(CMO)= 3,492
FY08 4-30-08 6,093 …Avid(CMO)= 5,897
FY09 4-30-09 18,151 …Avid(CMO)= 12,963
FY10 4-30-10 27,943 …Avid(CMO)= 13,204
FY11 4-30-11 13,492 …Avid(CMO)= 8,502
FY12 4-30-12 15,233 …Avid(CMO)= 14,783
FY13 4-30-13 21,683 …Avid(CMO)= 21,333
FY14 4-30-14 22,401 …Avid(CMO)= 22,294
FY15 4-30-15 26,781 …Avid(CMO)= 26,744
...Total Gov’t Revs from 7-2008 inception thru FY11Q1(Apr’11): $24.15mm
icon url

cjgaddy

10/08/15 7:32 AM

#238073 RE: cjgaddy #221526

The names of 3 New Bavi Trials (incl. AZN/Durvalumab & BMS/Opdivo) may well be these once they appear on https://www.clinicaltrials.gov . We'll see!

From: http://adisinsight.springer.com/search – updated 9-9-15:

“Phase I/Ib trial of bavituximab in combination with durvalumab in patients with multiple solid tumors”
PLANNING
Drugs: Bavituximab (Primary)
[Note: Durvalumab = AstraZeneca's anti-PD-L1 mab, aka MEDI4736]
Indications: Solid tumors
Phase of Trial: Phase I

“An open-label multi-center, randomized Phase II trial of the anti-PD-1 monoclonal antibody nivolumab (Opdivo) versus nivolumab plus bavituximab in patients with previously treated locally advanced or metastatic NSCLC”
PLANNING
Drugs: Bavituximab (Primary); Nivolumab
[Note: Opdivo(nivolumab) = Bristol-Myers Squibb's anti-PD-1 mab]
Indications: Non-small cell lung cancer
Phase of Trial: Phase II

“A phase II/III open-label trial of physician's choice of either docetaxel or paclitaxel with or without bavituximab in patients with locally advanced or metastatic HER2 negative breast cancer”
Planning
Drugs: Bavituximab (Primary)
Indications: Breast cancer
Phase of Trial: Phase II/III

= = = = = = = = = = = = = = = = =To The Best of My Knowledge:
9-2015 UPCOMING NEW BAVI TRIALS (per Dr.Hutchins 8-26-15/ImVacS & 9-9-15/CC) http://tinyurl.com/qz64pzg
...Ph.2 (PPHM 1501), Bavi+Optivo(nivolumab), 2ndLine NSCLC, squam+nonsquam (randomized, open-label)
...Ph.2/3 (PPHM 1502), Bavi+Paclitaxel-or-Docetaxel(Dr’sChoice), Early-Stage Her2- Breast Cancer
...Ph.2/3 (PPHM 1401), Bavi+neoadjuvant-paclitaxel, Her2- Met. Breast Cancer
6-1-15 New Bavi Trials planned: Ph2 Bavi+Opdivo/2L-NSCLC(Squamous+NonSquamous), Ph2/3 Bavi+Doce/PAC/Her2-Breast http://tinyurl.com/qxu4w2x





9-9-15 Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/ph22vdn
...CEO S.King: “The Memorial Sloan Kettering & AstraZeneca collaborations are an important part of our announced plans to expand our bavituximab clinical pgm.”
icon url

cjgaddy

01/03/16 9:53 AM

#247488 RE: cjgaddy #221526

3 Types of Interim Analyses: SAFETY, FUTILITY, EFFICACY. (SAFETY being a continuous DMC concern).

During a clinical trial, we can perform interim analysis (or DMC, DSMB review) for 3 different reasons:

Interim analysis for SAFETY:
1) with pre-specified stopping rule (for example stop the trial if we see # of cases of Serious Adverse Events)
2) without pre-specified stopping rule (rely on DMC members to review the overall safety)

Interim analysis for FUTILITY ["INFERIORITY"]: To see if the new treatment is unlikely to beat the control – then stop the trial for futility - this is called ‘futility analysis’.

Interim analysis for EFFICACY ["SUPERIORITY"]: To see if the new treatment is overwhelmingly better than control - then stop the trial for efficacy.

In situations 2 & 3, the criteria for stopping rule for efficacy could be different from the stopping rule for futility, but need to be pre-specified.

More: http://onbiostatistics.blogspot.com/2012/03/futility-analysis-in-clinical-trials.html

= = = = = = =
6-1-15 PR: BAVI CLINICAL TRIALS EXPANSION http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=915699
SUNRISE Phase III Pivotal Trial
The company's Phase III SUNRISE (Stimulating ImmUne RespoNse thRough BavItuximab in a PhaSE III Lung Cancer Study) is an approximately 600 patient trial that continues to enroll at over 150 sites worldwide. Completion of enrollment is anticipated by calendar year-end. This Phase III, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the safety, tolerability and efficacy of bavituximab as a second-line treatment in patients with non-squamous NSCLC. Enrollment is proceeding according to plan with 2 planned interim efficacy analyses which will be reviewed by the trial's Independent Data Monitoring Committee (IDMC). The 1st interim analysis, which will be conducted when 33% of the targeted overall survival events are reached, is for futility and the 2nd interim analysis, for futility or superiority [Superiority=EFFICACY], will be conducted at 50% of events. As these analyses are event driven, the exact timing of each is unknown, however the company plans to provide updates as these events are reached. For additional information about the SUNRISE trial, please visit http://www.sunrisetrial.com or ClinicalTrials.gov using the Identifier NCT01999673. => http://www.clinicaltrials.gov/ct2/show/NCT01999673

12-10-15: “Sunrise >90% enrolled; sufficient to allow the 2 planned interim looks (33%/50%) and final readout based on PrimEndPt=OS”
“The next milestones are the interim analyses that will be conducted when 33% & 50% of the targeted number of deaths are reached. While these are event driven, it is our expectation that the 1st interim analysis will read out in early 2016 and the 2nd interim analysis around mid-2016. The final analysis, which will trigger study unblinding, is currently projected to occur at the end of 2016.
http://tinyurl.com/jkp885g
icon url

cjgaddy

01/03/16 4:52 PM

#247519 RE: cjgaddy #221526

Rolf Brekken (PPHM/SAB) speaking 1-9-16 at Special AACR Tumor Microenvironment Conf. in San Diego. Note that the chair of Session5 that our Dr. Brekken is speaking in is Dr. Joan Massague, who is the DIRECTOR of Memorial Sloan Kettering Institute.

Jan7-10 2016: “AACR's The Function of Tumor Microenvironment in Cancer Progression Conf.”, SanDiego
“This AACR Special Conference will focus on discussing the emerging concepts in stromal cell and ECM heterogeneity, stromal cell metabolism, early events in carcinogenesis involving contributions from tumor cells and their microenvironment, stress responses to oxygen and nutrient gradients, translational impact of targeting the microenvironment, tumor immunity and immunotherapy.”
http://www.aacr.org/Meetings/Pages/Program-Detail.aspx?EventItemID=73&DetailItemID=419
1-9-16 10:30am-12:45pm: Plenary Session 5: “Actions of Innate & Adaptive Immunity”
Chairperson: Joan Massague**, Memorial Sloan Kettering Inst.
1. Tak Mak, Univ./Toronto, “Beyond checkpoint blockade: Emerging strategies”
2. Elizabeth Jaffee, Johns Hopkins, “Tipping the balance from a procarcinogenic to...”
3. Jeffrey Molldrem, MD Anderson, “T cell receptor-like antibody 8F4 targets leukemia...”
4. Joan Massague, MSK-CC, “Latency & immune evasion of metastatic stem cells”
5. Rolf A. Brekken (PPHM SAB), UTSW-MC/Dallas, “Antibody mediated blockade of phosphatidylserine synergizes with immune checkpoint blockade by inhibiting multiple immune suppressive mechanisms”
- - - - - - -
**Dr. Joan Massague is not just some doc from MSK, he is the DIRECTOR OF THE SLOAN KETTERING INSTITUTE and a very well-known scientist.
http://www.mskcc.org/research-areas/programs-centers/ski/director-joan-massague
Here is a video of Dr. Massague talking about the “Next Wave” of cancer research: https://www.mskcc.org/research-areas/programs-centers/ski

= = = = = = = = = =
5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos” http://tinyurl.com/qxu4w2x

7-14-15 Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/nw2v5u6
...CEO S.King: “We recently entered into collaboration with investigators at Memorial Sloan Kettering Cancer Ctr to continue expanding on this important work, as well as to explore other potential applications of bavituximab and other agents that target PS-signaling pathway.”

9-9-15 Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/ph22vdn
...CEO S.King: “The Memorial Sloan Kettering & AstraZeneca collaborations are an important part of our announced plans to expand our bavituximab clinical pgm.”

= = = = = = = = =
BAVI MOA 5-28-14: Dr. Rolf Brekken’s 47min CRI “Cancer Immunotherapy” webinar about Bavituximab as an Upstream/Global Immune Checkpoint Inhibitor – REPLAY: http://tinyurl.com/lxgftyx
. . .CRI=Cancer Research Institute (NYC – Supported by BMS): http://www.cancerresearch.org - Facebook: http://tinyurl.com/pbmhb2z , https://twitter.com/CancerResearch
. . .CRI launches “Answer to Cancer” (cancer immunotherapy) website http://www.theanswertocancer.org
. . .8-12-14: CRI adds Youtube links to the 5-28-14 CRI Immunotherapy webinar, incl. Dr. Brekken's talk "about Bavi and how it works against lung, liver, and other kinds of cancers" http://tinyurl.com/ps5h6h8
BAVI MOA 3-25-14: Dr. Rolf Brekken’s 40min talk at NYAS Lung Cancer Symposium http://tinyurl.com/lq9stnk (45 Slides)
. . .Dr.Brekken’s talk: “Antibody-mediated Inhibition of PS - A Novel Strategy for Immune Checkpoint Blockade” (the 5 speakers: Jessica Donington, Roy Herbst, Balazs Halmos, Suresh Ramalingam, Rolf Brekken)